NCT02770014 · REGISTRY CONDITION SEARCH

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2019-11-22

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Turnaround Time

→

outcome · POSTED

Positive Predictive Value (PPV) And False Negative Rate Of Plasma Genotyping

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed metastatic NSCLC including recurrent disease * EGFR genotype must not be known. However, pending EGFR tumor genotyping is allowed. --Participants with positive or pending EGFR mutation on plasma genotyping performed at the central lab are eligible for enrollment, and will not need to repeat initial plasma genotyping on study. * Tissue must be available for genotyping or biopsy planned to obtain tissue for genotyping. Biopsy requirement may be waived if not technically feasible and plasma genotyping reveals an eligible EGFR mutation (exon 19 del/L858R). Determination of technical feasibility must be made independently of plasma genotyping results. * Participants must possess at least two of the following clinical characteristics which enrich for EGFR mutations: * smoked less than 10 pack years * Asian race. * Adenocarcinoma (including adenosquamous carcinoma) on histology or cytology. * Participants must have measurable disease with at least one lesion that can be accurately measured in longest dimension as \>2 cm with conventional imaging techniques or \>1 cm with a spiral CT scan per RECIST v1.1. * Participants must have progressive, advanced cancer as defined by one of the following: * Newly diagnosed, untreated advanced disease * Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed). * Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment. Any number of prior therapies are acceptable excluding previous EGFR kinase inhibitors. * Age 18 years or older. * ECOG performance status 0-2. * Participant must be able to understand and give consent to participate in the study. * Patient must be a candidate for systemic therapy with erlotinib based on clinical assessment. Patients must meet the following criteria before beginning therapy (Note: these are not required for initial study enrollment and plasma genotyping): * ECOG performance status of 0-2 * Platelets \>75 * AST \& ALT \< 3x the upper limit of normal * Creatinine clearance \> 30 mL/min by Cockroft-Gault * No other contraindication to erlotinib * Female participants of child-bearing age must agree to use adequate contraception (hormonal, barrier or abstinence) for the duration of the study while receiving erlotinib and undergo a pregnancy test. Any evidence or suspicion of pregnancy should be reported to the treating physician immediately. * Male participants must agree to use adequate contraception for the duration of the study while receiving erlotinib Exclusion Criteria: * Participants must not have had chemotherapy within the past 10 days. * Participants must not have had prior treatment with an EGFR kinase inhibitor, EGFR directed therapy or investigational agent. * Participants must not have residual adverse events from previous therapy greater than CTCAE v4.0 grade 2 at the time of registration. * Participants must not have symptomatic brain metastases or brain metastases requiring steroids. Asymptomatic brain metastases not requiring steroids are acceptable. * Participant must not have a history of allergy to erlotinib. * Second primary cancer which is active and requiring treatment. * Participants must not be pregnant or breastfeeding
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
intervention Names
Drug: Erlotinib
label
EGFR mutation Positive, Treatment With Erlotinib
type
EXPERIMENTAL

interventions

arm Group Labels
EGFR mutation Positive, Treatment With Erlotinib
name
Erlotinib
other Names
Tarceva
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 43
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of participants who were alive with evidence of complete or partial response, evaluated using RECIST 1.1 criteria. Patients that underwent rapid plasma genotyping and had an EGFR mutation and who were treated with erlotinib were included in this calculation.
measure
Overall Response Rate
time Frame
From date of erlotinib initiation until the date of first documented disease progression or date of death from any cause, whichever came first. ORR was assessed up to 21 months after erlotinib initiation.

secondary Outcomes

description
The turnaround time from study registration to treatment initiation was recorded for the plasma genotyping strategy versus standard tumor genotyping. For rapid plasma genotyping, turnaround time is the time between ordering plasma genotyping and obtaining results; this time period was compared to the turnaround time of obtaining the tumor genotyping results.
measure
Turnaround Time
time Frame
Maximum 38 days
description
Concordance between results of plasma genotyping and tumor genotyping, among patients with tissue available for standard genotyping
measure
Positive Predictive Value (PPV) And False Negative Rate Of Plasma Genotyping
time Frame
PPV and False Negative Rate can be assessed when plasma and tissue results are available for each patient; average plasma result turnaround time was 4 days, versus average of 20 days for tissue result turnaround time.

Full study description

brief Summary: Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.
detailed Description: This research study is a Phase II clinical trial. This research study will determine if a rapid blood test can be used to detect EGFR mutations in patients with newly diagnosed lung cancer and use that information to rapidly start patients on a pill-based therapy. This blood test has not previously been used to select patients for treatment with Erlotinib without confirming this finding on a biopsy.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-37b0ce11a501a338f7e0
requested nct id
NCT02770014
primary nct id
NCT02770014
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
a315882a3d794ff45172a5cc464c1f94e38e31ce8753e493baca3bfb62371250
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-37b0ce11a501a338f7e0
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02770014
occurrences
context exact
NCT02770014
end
11
exact text
NCT02770014
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/506/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f4acca745a8103712837d885aad276373f5284f802a328815f30d938c0517782
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice